Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
The study found that andexanet alfa significantly improves hemostatic efficacy in patients with intracerebral hemorrhage on factor Xa inhibitors but increases the risk of thrombotic events. These findings highlight the need for careful patient selection and monitoring when considering andexanet alfa in clinical practice.
Hematology May 20th 2024
Cleveland Clinic Journal of Medicine
Managing venous thromboembolism effectively demands a nuanced understanding of updated clinical guidelines, which now differentiate treatment protocols based on specific risk assessments and patient comorbidities.
Cardiology April 15th 2024
The Epoch Times
Researchers have uncovered a promising link between sulforaphane, a natural chemical in cruciferous vegetables, and improved outcomes in stroke treatment. This compound offers a novel approach to enhancing the effectiveness of existing therapies without the associated risk of bleeding.
Cardiology April 9th 2024
For patients with cirrhosis facing venous thromboembolic events, the choice of anticoagulant—be it DOACs or LMWH—demands careful consideration of their unique hemostatic profile, emphasizing the need for personalized treatment strategies.
Gastroenterology February 22nd 2024
Venous thromboembolism presents a significant challenge in cancer care, with emerging evidence supporting the use of direct oral anticoagulants for improved outcomes. This highlights the evolving landscape of VTE management in oncology, stressing the importance of personalized treatment strategies.
Hematology/Oncology February 20th 2024
In the complex landscape of post-cardiac surgery care, the incidence of new-onset PCSAF presents a significant challenge, necessitating a judicious approach to anticoagulation to prevent thromboembolic events while minimizing bleeding risks.
Cardiology February 14th 2024